ArticleMolecules (Basel, Switzerland)2023
Quercitrin Is a Novel Inhibitor of
Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Biofluid-derived exosomes as next-generation biotherapeutic platforms to combat multidrug-resistant bacterial infections.Regenerative biomaterials · 2026Review
- Industrial Applications of Different Parts of FlatlandPlants (Basel, Switzerland) · 2025Article
- Berberine Hydrochloride Reduces the Intracellular Survival ofBiomolecules · 2025Article
- Inhibition of the Type III Secretion System of Salmonella Enterica Serovar Typhimurium and Alleviation Pathogenicity Via Treatment with Xanthotoxol.Current microbiology · 2025Article
- Antibiotic Alternatives and Next-Generation Therapeutics forAntibiotics (Basel, Switzerland) · 2025Review
- Targeting Type III Secretion System usingIndian journal of microbiology · 2025Review
- Naringenin targets FimZ to regulate type I fimbriae and reduce the virulence ofFrontiers in cellular and infection microbiology · 2025Article
- Salmonellosis: An Overview of Epidemiology, Pathogenesis, and Innovative Approaches to Mitigate the Antimicrobial Resistant Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Type III Secretion System in Intestinal Pathogens and Metabolic Diseases.Journal of diabetes research · 2024Review
- Pyroptosis regulation byFrontiers in immunology · 2024Review
- Canagliflozin Inhibited the Activity of Hemolysin and Reduced the Inflammatory Response Caused byInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
The purpose was to screen type III secretory system (T3SS) inhibitors of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.